Understanding how HIV DNA integrates into human cells
Biochemical Mechanism of HIV DNA Integration
This study is looking at how the HIV virus inserts its DNA into our cells, which is an important part of how it works, and by understanding this better, researchers hope to find new ways to treat or even cure HIV for patients.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10988580 on NIH RePORTER |
What this research studies
This research investigates the biochemical mechanisms behind HIV-1 DNA integration into human chromosomes, a crucial step in the virus's lifecycle. By studying the interactions between the HIV integrase enzyme and host proteins, particularly LEDGF/p75, the research aims to uncover how this process enhances HIV pathogenesis. The team utilizes advanced techniques to determine the 3D structures of the integrase and its binding partners, which could lead to the development of new therapeutic strategies. Patients may benefit from insights that could inform more effective treatments or potential cures for HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are seeking new treatment options or those who have not yet started antiretroviral therapy.
Not a fit: Patients who are not infected with HIV or those who have advanced AIDS with limited treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of novel therapies that more effectively combat HIV infection and improve patient outcomes.
How similar studies have performed: Previous research has shown promise in targeting integrase and its interactions, indicating that this approach could lead to significant advancements in HIV treatment.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Engelman, Alan N. — Dana-Farber Cancer Inst
- Study coordinator: Engelman, Alan N.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.